Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Martek Biosciences Corporation

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Martek Biosciences Corporation (NASDAQ: MATK) (referred to as "Martek" or the “Company”) by Royal DSM N.V. (“DSM”) in an all cash tender offer valued at approximately US$1.087 billion (about euro 829 million).

Under the terms of the agreement, DSM will pay $31.50 per share in cash in exchange for each share of Martek in the proposed acquisition. The acquisition is structured as an all-cash tender offer for all the outstanding shares of Martek common stock to be followed by a merger in which each remaining share of Martek common stock would be converted into the same cash per share price paid in the tender offer. The tender offer is expected to commence between January 10, 2011 and January 25, 2011.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders. If you are a holder of Martek stock and want to discuss your legal rights, you may e-mail or call Bull & Lifshitz, LLP who will, without obligation or cost to you, attempt to answer your questions.

If you are a shareholder of Martek and would like more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail]. All e-mail correspondence should make reference to Martek.

Bull & Lifshitz, LLP is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.nyclasslaw.com.

ATTORNEY ADVERTISING. © 2010 Bull & Lifshitz, LLP. The law firm responsible for this advertisement is Bull & Lifshitz, LLP, 18 East 41st Street, New York, New York 10017, [phone]. Prior results do not guarantee or predict a similar outcome with respect to any future matter.